PMID- 35331231
OWN - NLM
STAT- MEDLINE
DCOM- 20220328
LR  - 20220401
IS  - 1475-2875 (Electronic)
IS  - 1475-2875 (Linking)
VI  - 21
IP  - 1
DP  - 2022 Mar 24
TI  - Malaria chemoprevention and drug resistance: a review of the literature and 
      policy implications.
PG  - 104
LID - 10.1186/s12936-022-04115-8 [doi]
LID - 104
AB  - Chemoprevention strategies reduce malaria disease and death, but the efficacy of 
      anti-malarial drugs used for chemoprevention is perennially threatened by drug 
      resistance. This review examines the current impact of chemoprevention on the 
      emergence and spread of drug resistant malaria, and the impact of drug resistance 
      on the efficacy of each of the chemoprevention strategies currently recommended 
      by the World Health Organization, namely, intermittent preventive treatment in 
      pregnancy (IPTp); intermittent preventive treatment in infants (IPTi); seasonal 
      malaria chemoprevention (SMC); and mass drug administration (MDA) for the 
      reduction of disease burden in emergency situations. While the use of drugs to 
      prevent malaria often results in increased prevalence of genetic mutations 
      associated with resistance, malaria chemoprevention interventions do not 
      inevitably lead to meaningful increases in resistance, and even high rates of 
      resistance do not necessarily impair chemoprevention efficacy. At the same time, 
      it can reasonably be anticipated that, over time, as drugs are widely used, 
      resistance will generally increase and efficacy will eventually be lost. 
      Decisions about whether, where and when chemoprevention strategies should be 
      deployed or changed will continue to need to be made on the basis of imperfect 
      evidence, but practical considerations such as prevalence patterns of resistance 
      markers can help guide policy recommendations.
CI  - (c) 2022. The Author(s).
FAU - Plowe, Christopher V
AU  - Plowe CV
AUID- ORCID: 0000-0002-0045-9888
AD  - University of Maryland School of Medicine, Baltimore, MD, USA. 
      plowe.chris@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220324
PL  - England
TA  - Malar J
JT  - Malaria journal
JID - 101139802
RN  - 0 (Drug Combinations)
RN  - 88463U4SM5 (Sulfadoxine)
RN  - Z3614QOX8W (Pyrimethamine)
SB  - IM
MH  - Chemoprevention/methods
MH  - Drug Combinations
MH  - Drug Resistance/genetics
MH  - Female
MH  - Humans
MH  - Infant
MH  - *Malaria/drug therapy/prevention & control
MH  - Policy
MH  - Pregnancy
MH  - Pyrimethamine/therapeutic use
MH  - *Sulfadoxine/therapeutic use
PMC - PMC8943514
COIS- The author has no conflicts of interest to declare.
EDAT- 2022/03/26 06:00
MHDA- 2022/03/29 06:00
PMCR- 2022/03/24
CRDT- 2022/03/25 05:30
PHST- 2022/01/31 00:00 [received]
PHST- 2022/03/03 00:00 [accepted]
PHST- 2022/03/25 05:30 [entrez]
PHST- 2022/03/26 06:00 [pubmed]
PHST- 2022/03/29 06:00 [medline]
PHST- 2022/03/24 00:00 [pmc-release]
AID - 10.1186/s12936-022-04115-8 [pii]
AID - 4115 [pii]
AID - 10.1186/s12936-022-04115-8 [doi]
PST - epublish
SO  - Malar J. 2022 Mar 24;21(1):104. doi: 10.1186/s12936-022-04115-8.